Promising Findings: Magnolia Tree Bark Extract Halts SARS-CoV-2 Replication in Specific Cells, Paving the Way for Future Coronavirus Treatments – Including MERS and SARS-CoV

A recent study conducted by a team of researchers from the Netherlands has revealed promising findings regarding the inhibitory effects of honokiol, a compound derived from various species of magnolia tree bark, on the replication of the SARS-CoV-2 virus. The study, published in Microbiology Spectrum, a reputable journal of the American Society for Microbiology, sheds light on honokiol’s ability to hinder viral replication in multiple cell types.

Through their experiments, the researchers observed a significant decrease in the production of infectious SARS-CoV-2 particles within treated cells. In fact, the levels dropped to approximately one-thousandth of the previous amount, indicating the compound’s potential as an effective antiviral agent against the virus.

Notably, honokiol exhibited inhibitory effects not only on SARS-CoV-2 but also on other highly pathogenic human coronaviruses, including MERS-CoV and SARS-CoV. This broader antiviral activity suggests honokiol’s potential to combat a range of viral infections.

The findings suggest “it has a broad spectrum of activity and would likely also inhibit novel coronaviruses that might emerge in the future,” points out Martijn J. van Hemert. 

The driving force behind this research stemmed from the insufficient availability of vaccines and treatments during the initial stages of the pandemic. The primary objective was to ensure preparedness for future outbreaks of novel coronaviruses. In light of this, van Hemert stressed that his team, alongside global counterparts, proactively investigated numerous compounds to assess their potential as antiviral agents against COVID-19.

“If honokiol can be developed into a drug, possibly in combination with other compounds, stockpiling it would help us to increase our preparedness for the emergence of the next coronavirus,” adds van Hemert. “Broad-spectrum drugs could then be used to treat early patients and prevent spread, or they could be used prophylactically among healthcare workers, and in high-risk groups, such as among nursing home residents.” 

Honokiol, a natural compound, possesses notable anti-inflammatory properties, as highlighted by van Hemert, a renowned expert in the field. This characteristic can prove beneficial in situations where patients delay seeking medical treatment until the disease has progressed to a relatively advanced stage, which unfortunately occurs quite frequently. By this time, the body’s own inflammatory responses to the infection start causing symptoms.

“At that point, inhibition of virus replication might no longer be helpful, but honokiol’s anti-inflammatory response might mitigate the illness,” according to van Hemert.

Moreover, honokiol exerts its inhibitory effects on a later stage of the viral replication cycle, specifically after the virus has penetrated the host cell. The researchers suspect that honokiol achieves this by initiating processes within the host cell that impede the replication of the virus. This inhibitory action has been observed in both the original SARS-CoV-2 variants and the more recent omicron variants, providing promising evidence of honokiol’s broad-spectrum antiviral capabilities.

At this early stage in the research, “Our study merely provides the basis for further research into potential therapeutic applications,” adds van Hemert. “It is important to mention that it is too early to claim that honokiol might be used in SARS-CoV-2 patients. This requires much more research and—if successful—properly conducted clinical trials.” 

Image Credit: LONG WEI / Feature China/Future Publishing via Getty Images